European Journal of Surgical Oncology
Volume 35, Issue 11 , Pages 1137-1145 , November 2009

The role of PET in the surgical approach to adrenal disease

  • M.D. Gross

      Affiliations

    • Department of Radiology, Division of Nuclear Medicine, University of Michigan Medical Center and Department of Veterans Affairs Health System, Ann Arbor, Michigan USA
    • Corresponding Author InformationCorresponding author. Milton D Gross M.D., Chief, Nuclear Medicine Service (115), Department of Veterans Affairs Health System, 2215 Fuller Rd, Ann Arbor, Michigan 48105, USA. Tel.: +1 734 845 3082; fax: +1 734 845 3278.
    • ,
  • P.G. Gauger

      Affiliations

    • Department of Surgery, Division of Endocrine Surgery, University of Michigan Medical Center, Ann Arbor, Michigan USA
    • ,
  • M. Djekidel

      Affiliations

    • Department of Radiology, Division of Nuclear Medicine, University of Michigan Medical Center and Department of Veterans Affairs Health System, Ann Arbor, Michigan USA
    • ,
  • D. Rubello

      Affiliations

    • Department of Nuclear Medicine, PET Center, ‘Santa Maria della Misericordia’ Hospital, Rovigo, Italy
    • Corresponding Author InformationCorresponding author. Domenico Rubello M.D., Chief, Nuclear Medicine Service, PET Center, Director, Department of Radiology, Medical Physics and Nuclear Medicine, Santa Maria della Misericordia Hospital, Viale Tre Martiri 140, 45100 Rovigo, Italy. Tel.: +39 39 4431; fax: +39 39 4427.

,Accepted 23 January 2009.

References 

  1. Gross MD, Korobkin M, Hussain H, et al. Adrenal gland imaging. In:  Jameson JL,  Degroot LJ editor. Endocrinology. 5th ed. Philadelphia: W.B. Saunders; 2005;p. 2425–2453[Chapter 126]
  2. Gross MD, Wong K-K, Rubello D. Scintigraphic imaging of adrenal disease. Minerva Endocrinol; in press.
  3. Counsell RE, Ranade VV, Blair RJ, et al. Tumor localizing agents. Ix. Radioiodinated cholesterol. Steroids. 1970;16:317–328
  4. Blair RJ, Beierwaltes WH, Lieberman LM. Radiolabeled cholesterol as an adrenal scanning agent. J Nucl Med. 1971;12:176–182
  5. Beierwaltes WH, Lieberman LM, Ansari AA, et al. Visualization of human adrenal glands by in vivo scintillation scanning. JAMA. 1971;216:275–277
  6. Basmadjian GP, Hetzel KR, Ice RD, et al. Synthesis of a new adrenal cortex imaging agent 6-131I-iodomethyl-19-norcholest-5(10)-en-3-ol (NP-59). J Labeled Compd. 1975;11:427–432
  7. Sarkar SD, Beierwaltes H, Ice RD, et al. A new and superior adrenal scanning agent, NP-59. J Nucl Med. 1975;16:1038–1042
  8. Thrall JH, Freitas JE, Beierwaltes WH. Adrenal scintigraphy. J Nucl Med. 1978;18:23–41
  9. Shapiro B, Britton KE, Hawkins LA, et al. Clinical experience with 75Se-selenomethylnorcholesterol adrenal imaging. Clin Endocrinol. 1981;15:19–27
  10. Jonson SD, Welch MJ. Synthesis, biological evaluation, and baboon PET imaging of the potential adrenal imaging agent cholesteryl-p-[18F]fluorobenzoate. Nucl Med Biol. 1999;26:131–138
  11. Beierwaltes WH, Wieland DM, Yu T, et al. Adrenal imaging agents: rationale, synthesis, formulation and, metabolism. Semin Nucl Med. 1978;8:5–12
  12. Pacak K, Eisenhofer G, Goldstein DS. Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev. 2004;25:568–580
  13. Minn H, Salonen A, Friberg J, et al. Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. J Nucl Med. 2004;45:972–979
  14. Zettinig G, Mitterhauser M, Wadsak W, et al. Positron emission tomography imaging of adrenal masses: 18F-fluorodeoxyglucose and the 11β-hydroxylase tracer 11C-metomidate. Eur J Nucl Med Mol Imaging. 2004;31:1224–1230
  15. Wadsak W, Mitterhauser M, Rendl G, et al. [18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. Eur J Nucl Med Mol Imaging. 2006;33:669–672
  16. Gross MD, Avram A, Fig LM, et al. Positron emission tomography in the diagnostic evaluation of adrenal tumors. Q J Nuclear Med Mol Imaging. 2007;51:260–271
  17. Lieberman LM, Beierwaltes WH, Varma VM, et al. Labeled dopamine concentration in human adrenal medulla and in neuroblastoma. J Nucl Med. 1969;10:93–97
  18. Anderson BG, Beierwaltes WH, Harrison TS, et al. Labeled dopamine concentration in pheochromocytomas. J Nucl Med. 1973;14:781–784
  19. Fowler JS, MacGregor RR, Wolf AP. Radiopharmaceuticals. Halogenated dopamine analogs: synthesis and radiolabeling of 6-iododopamine and tissue distribution studies in animals. J Med Chem. 1976;19:356–360
  20. Korn N, Buswink A, Yu T, et al. Aradioiodinated bretylium analog as a potential agent for scanning the adrenal medulla. J Nucl Med. 1977;18:87–89
  21. Wieland DM, Wu JL, Brown LE, et al. Radiolabeled adrenergic neuron blocking agents: adrenal medulla imaging with (131I) iodobenzylguanidine. J Nucl Med. 1980;21:349–353
  22. Wieland DM, Brown LE, Tobes MC, et al. Imaging the primate adrenal medulla with (123I) and (131I) metaiodobenzylguanidine. J Nucl Med. 1981;22:358–364[Concise communication]
  23. Sisson JC, Frager MS, Valk TW, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med. 1981;305:12–17
  24. Valk TW, Frager MS, Gross MD, et al. Spectrum of pheochromocytoma in multiple endocrine neoplasia: a scintigraphic portrayal using 131-I-metaiodobenzylguanidine. Ann Intern Med. 1981;94:762–767
  25. Nakajo M, Shapiro B, Copp J, et al. The normal and abnormal distribution of the adrenomedullary imaging agent I-131-metaiodobenzylguanidine (I-MIBG) in man: evaluation by scintigraphy. J Nucl Med. 1983;24:672–682
  26. Fitzgerald PA, Goldsby RE, Huberty JP, et al. Malignant pheochromocytomas and paragangliomas. A phase II study of therapy with high dose 131I-metaiodobenzlyguanidine (131I-MIBG). Ann NY Acad Sci. 2006;1073:465–490
  27. Rosenspire KC, Haka MS, Jewett DM, et al. Synthesis and preliminary evaluation of (11C) metahydroxyephedrine: a false neurotransmitter agent for heart neuronal imaging. J Nucl Med. 1990;31:1328–1334
  28. Schwaiger M, Kalff V, Rosenspire KC, et al. The noninvasive evaluation of the sympathetic nervous system in the human heart by PET. Circulation. 1990;82:457–464
  29. Nilsson O, Jakobsen AM, Kolby L, et al. Importance of vesicle proteins in the diagnosis and treatment of neuroendocrine tumors. Ann NY Acad Sci. 2004;1014:280–283
  30. Ilias I, Pacak K. Anatomical and functional imaging of metastatic pheochromocytoma. Ann New York Acad Sci. 2004;1018:495–504
  31. Eriksson B, Bergström M, Sundin A, et al. The role of PET in the localization of neuroendocrine and adrenocortical tumors. Ann NY Acad Sci. 2002;970:159–169
  32. Ruffini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Sem Nucl Med. 2006;36:228–247
  33. Van der Harst E, de Herder WW, Bruining HA, et al. 123I-metaiodobenzylguanidine and 111In-octreotide uptake in benign and malignant pheochromocytomas. J Clin Endo Metab. 2001;86:685–693
  34. Chen L, Li F, Zhuang H, et al. Cardiac pheochromocytomas detected by Tc-99m-Hydrazinonicotinyl-Tyr3-Octreotide (HYNIC-TOC) scintigraphy. Clin Nucl Med. 2007;32:182–185
  35. Win Z, Al-Nahhas A, Towey D, et al. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun. 2007;28:359–363
  36. Yun M, Kim W, Alnafisi N, et al. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001;42:1795–1799
  37. Metser U, Miller E, Lerman H, et al. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med. 2006;47:32–37
  38. Khan TS, Sundin A, Juhlin C, et al. 11C-metomidate imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging. 2003;30:403–410
  39. Hennings J, Lindhe Ö, Bergström M, et al. [11C]Metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab. 2006;91:1410–1414
  40. Mackie GC, Shulkin BL, Ribero RC, et al. Use of [18F]-fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91:2665–2671
  41. Tenenbaum F, Groussin L, Foehrenbach H, et al. 18F-fluorodeoxyglucose positron emission tomography as a diagnostic tool for maliganacy of adrenocortical tumors? Preliminary results in 13 consecutive patients. Eur J Endocrinol. 2004;150:789–792
  42. Fassnacht M, Kenn W, Allolio B. Adrenal tumors: how to establish malignancy?. J Endocrinol Invest. 2004;27:387–399
  43. Rao SK, Caride VJ, Ponn R, et al. F-18 fluorodeoxyglucose positron emission tomography-positive benign adrenal cortical adenoma: imaging features and pathologic correlation. Clin Nucl Med. 2004;29(5):300–302
  44. Caroili EM, Korobkin M, Brown RKJ, et al. Differentiating adrenal adenomas from nonadenomas using 18F-FDG PET/CT: quantitative and qualitative evaluation. Acad Radiol. 2007;14:468–475
  45. White ML, Cho KJ, Gauger PG. et al. The role of radiologic studies in the evaluation and management of primary hyperaldosteronism, Surgery; in press.
  46. Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev. 1995;16:460–484
  47. Maurea S, Klain M, Mainolfi C, et al. The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses. J Nucl Med. 2001;42:884–892
  48. Maurea S, Caraco C, Klain M, et al. Imaging characterization of non-hypersecreting adrenal masses. Comparison between MR and radionuclide techniques. Q J Nucl Med Mol Imaging. 2004;48:188–197
  49. Houseni M, Griggs W, Prini R, et al. Diagnosis of adrenal disease on PET/CT studies by standard uptake value measurement. Clin Nucl Med. 2008;33:74
  50. Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer. Recommendation of an international consensus conference. Endocr Relat Cancer. 2005;12:667–680
  51. Shimizu A, Oriuchi N, Tsushima Y. High [18F] 2-fluoro-2-deoxy-d-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing's syndrome. Ann Nucl Med. 2003;17(5):403–406
  52. Chong S, Lee KS, Kim HY, et al. Integrated PET/CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficiacy and interpretation pitfalls. Radiographics. 2006;26:1811–1826
  53. Elaini R, Shetty AB, Chapman S, et al. Improved detection and characterization of adrenal disease with PET-CT. Radiographics. 2007;27:755–767
  54. Ilias I, Sahdev A, Reznek RH, et al. The optimal imaging of adrenal tumours: a comparison of different methods. Endocrine-Related Cancer. 2007;14:587–599
  55. Shulkin BL, Ilias I, Sisson JC, et al. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann NY Acad Sci. 2006;1073:374–382
  56. Shapiro B, Sisson JC, Beierwaltes WH. Experience with the use of 131-I-metaiodobenzylguanidine for locating pheochromocytomas. In:  Raynaud C editors. Nuclear medicine and biology. vol. II:Paris: Pergamon Press; 1982;p. 1265
  57. Shapiro B, Sisson JC, Lloyd R, et al. Malignant pheochromocytoma: clinical, biochemical and scintigraphic characterization. Clin Endocrinol. 1984;20:189–203
  58. Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated peochromocotma and paprganglioma. J Clin Oncol. 2007;25:2262–2269
  59. Ilias I, Chen CC, Crrasquillo JA, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49:1613–1619
  60. Shulkin BL, Thompson NW, Shapiro B, et al. .Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET. Radiology. 1999;212:35–41
  61. Mamede M, Carrasquillo JA, Chen CC, et al. Discordant localization of 2-[18F]-fluoro-2-deoxy-d-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. Nucl Med Commun. 2006;27(1):31–36
  62. Ilias I, Shulkin B, Pacak K. New functionqal imaging modalities for chromaffin tumors, neuroblastoma and ganglioneuromas. Trends Endocrinol Metabol. 2005;16:66–72
  63. Trampal C, Engler H, Juhlin C, et al. Pheochromocytomas: detection with 11C Hydroxyephedrine PET. Radiology. 2004;230:423–428
  64. Ilias I, Jorge JY, Carrasquillo JA, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintography in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003;88:4083–4087
  65. Mackenzie IS, Gurnell M, Balan KK, et al. The use of 18-fluoro-dihydroxyphenalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma. Eur J Endocrinol. 2007;157:53–537
  66. Timmers HJ, Hadi M, Carrasquillo JA, et al. The effects of carbidopa on uptake on 6-18F-Fluoro-l-DOPA in PET of Pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med. 2007;48:1599–1606
  67. Ilias I, Pacak K. Diagnosis and management of tumors of the adrenal medulla. Horm Metab Res. 2005;37:717–721
  68. Bombardieri E, Seregni E, Villano C, et al. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med. 2004;48:150–163
  69. Miskulin J, Shulkin BL, Doherty GM, et al. Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma?. Surgery. 2003;134:918–922
  70. Greenblatt DY, Shenker Y, Chen H. The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma. Ann Surg Oncol. 2008;15:900–905
  71. Kaji P, Carrasquillo JA, Linehan WM, et al. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with Von Hipple–Lindau syndrome. Eur J Endocrinol. 2007;156:483–487
  72. Kalff V, Shapiro B, Lloyd R, et al. The spectrum of pheochromocytoma in hypertensive patients with neurofibromatosis. Arch Intern Med. 1982;142:2092–2097
  73. Shulkin BL, Shapiro B. Radioiodinated meta-iodobenzylguanidine in the management of neuroblastoma. In:  Pochedly C editors. Neuroblastoma. Boca Raton, FL: CRC Press; 1990;p. 171–198
  74. Gelfand MJ. Metaiodobenzylguanidine in children. Semin Nucl Med. 1993;23:231–242
  75. Shulkin BL, Wieland DM, Baro ME, et al. PET studies of neuroblastoma with carbon 11-hydroxyephedrine. J Nucl Med. 1993;33:220

PII: S0748-7983(09)00030-4

doi: 10.1016/j.ejso.2009.01.010

European Journal of Surgical Oncology
Volume 35, Issue 11 , Pages 1137-1145 , November 2009

Article Tools

* Image Usage & Resolution